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Abstract
Background: Percutaneous endoscopic gastrostomy (PEG) allows long-term tube feeding. Safety of pull-type and
introducer PEG placement in oncology patients with head/neck or oesophageal malignancies is unknown.
Methods: Retrospective analysis of 299 patients undergoing PEG tube placement between January 2006 and
December 2008 revealed 57 oncology patients. All patients with head/neck or oesophageal malignancy were
treated with chemo- and radiotherapy. In case of high-grade stenosis introducer Freka
® Pexact PEG tube was
placed (n = 24) and in all other patients (n = 33) conventional pull-type PEG tube. Short-term complications and
mortality rates were compared.
Results: Patients’ characteristics and clinical status were comparable in both groups. Short-term complications
were encountered in 11/24 (48%) introducer PEG patients as compared to only 4/33 (12%) pull-type PEG patients
(P < 0.05). Accidental removal of the introducer PEG tube occurred in 4/24 (17%) with need for surgical
intervention in 1 vs. 0/33 (0%, P < 0.05). Wound infection occurred in 3/24 (12%) leading to septic shock and
admission to intensive care unit (ICU) in 1 vs. 3/33 (9%, NS). Finally, 3/24 gastrointestinal perforations (12%) resulted
from a difficult placement procedure vs. 1/33 (3%), leading to urgent surgical intervention and admission to ICU.
Two introducer PEG patients died at ICU, resulting in an overall mortality rate of 8% vs. 0% (P = 0.091).
Conclusion: The introducer Freka
® Pexact PEG procedure for long-term tube feeding may lead to significantly
higher complication and mortality rates in patients with head/neck or oesophageal malignancies treated with
chemo- and radiotherapy. It is suggested to use the conventional pull-type PEG tube placement in this group of
patients, if possible.
Background
Percutaneous endoscopic gastrostomy (PEG) was first
performed in 1979 using the pull-type technique [1].
Since then feeding tubes have been adapted, but the
pull-type technique is still the standard procedure for
endoscopic PEG placement [2]. It allows longterm tube
feeding, when oral feeding is not possible, or when extra
feeding is necessary [3]. PEG placement involves an
upper gastrointestinal (GI) endoscopy, usually under
conscious sedation and with the use of local anesthesia
at the gastrostomy site. Prophylactic use of antibiotics is
advisable [4]. After inflation of air into the stomach in
order to obtain maximal apposition of the gastric and
abdominal walls, the gastrostomy site is located based
on the combination of light transillumination and finger
indentation of the abdominal wall. In the pull-type pro-
cedure the feeding tube is pulled through the mouth
into the stomach and through the abdominal wall. How-
ever, in several clinical situations the classical pull-type
PEG procedure is not possible or contraindicated. In
case of high-grade stenosis caused by an oesophageal
tumor or a head and neck tumor, a conventional upper
GI endoscopy may not be possible or the internal bum-
per of the PEG-tube may not pass. Also, the risk of
entmetastases at the site of the gastrostomy is real [5].
Finally, high volume ascites in the abdominal cavity is
also a contraindication for a pull-type PEG procedure
because of the risk of leakage [6,7].
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to the development of the introducer PEG, with or with-
out the combination of a gastropexy [6-9]. After filling
the stomach with air and locating the site of puncture by
means of light transillumination and finger indentation, 2
or 4 sutures are applied under endoscopic guidance using
a specifically designed introducer needle, resulting in a
gastropexy of the anterior gastric wall to the ventral
abdominal wall (Figure 1). Next, a trocar with a peal-
away sheet is introduced through the abdominal wall into
the stomach (Figure 2). Alternatively, a guidewire is
introduced via the Seldinger technique and the peal-away
sheet is introduced after progressive dilation of the gas-
trostomy. Finally the feeding tube is progressed through
the sheet which is then pealed off. An inflatable balloon
at the tip of the feeding tube serves as internal bumper.
Depending on the technique, the feeding tube is either
temporary or definitive. This technique can be used in
case of high grade stenosis since it allows transnasal
endoscopy using an ultra thin endoscope, even without
sedation [10]. Thanks to the gastropexy, this technique
can also be safely used in case of ascites [6].
Patients with oesophageal or head and neck malignant
tumors may need tube feeding because of poor oral
food intake due to malignant stenosis or due to radia-
tion- and chemotherapy-induced oesophagitis [11].
Often PEG-tube feeding is mandatory. In these cases
one may argue that the introducer PEG tube may serve
better. However, little is known on the outcome of
introducer PEG tubes in these patients. This study ret-
rospectively analyzed the outcome and short-term com-
plications of both pull-type and introducer PEG tubes in
oncology patients with oesophageal or head and neck
malignancies.
Methods
All medical records were reviewed of patients who
underwent PEG tube placement at the Antwerp Univer-
sity Hospital Endoscopy Unit from January 2006 until
December 2008. The local ethical committee of the
Antwerp University approved the retrospective analysis
of the medical files. All patients or their relatives pro-
vided informed consent for the PEG procedure. In total
299 procedures were performed. All oncology patients
with oesophageal or head and neck malignancies were
selected. Indication for PEG tube feeding was made by
the treating oncologist. PEG tube was placed 1 day
before the start of combined radiotherapy and che-
motherapy in all cases. Introducer PEG placement with
gastropexy (Freka
® Pexact Fr 15, Fresenius Kabi AG,
Bad Homburg, Germany) was only performed in case of
high-grade malignant stenosis, rendering the use of a
conventional upper GI endoscope difficult or impossible.
The decision to choose between pull-type and introdu-
cer PEG was at the discretion of the endoscopist. The
introducer PEG procedure is shown in Figures 1 and 2.
Whenever possible, conventional pull-type PEG (Freka
®
PEG-Set Gastric Fr 15 & 20, Fresenius Kabi AG, Bad
Homburg, Germany and Flocare PEG Set Fr 18, Nutri-
cia, Schiphol Airport, The Netherlands) placement was
performed. All procedures were performed by staff
members in collaboration with trainees. They were
assisted by an endoscopy nurse during the procedure.
Finally, results of the pull-type and push-type PEG pro-
cedures were compared in the selected group of oncol-
ogy patients. Data on patients’ age, sex, serum albumin,
WHO performance status, sedation and short term
complications (within 8 weeks after PEG placement)
were retrospectively collected and were statistically
Figure 1 Freka
® Pexact procedure showing the double needle to create a 2-suture gastropexy.
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tinuous variables and Mann-Withney test in case of dis-
continuous variables and Chi square test for
contingency table statistics. P < 0.05 was considered sta-
tistically significant. Results of continuous variables are
expressed as mean ± SEM (standard error of the mean)
and results of discontinuous variables as median with
25
th and 75
th percentile. The WHO (World Health
Organization) performance status is a scale for assessing
general health, ranging from 0 (healthy) to 5 (death)
[12].
Results
Of the 299 PEG procedures performed, 57 involved
oncology patients with oesophageal (n = 9) or head and
neck malignant tumors (n = 48). All procedures were
performed under conscious sedation using midazolam,
administered according to the patients’ needs. Linisol
2% was used for local anesthesia of the abdominal wall.
All patients received intravenous antibiotic prophylaxis
with either amoxiciline-clavulanic acid, levofloxacine or
cefacidal, except for 3 patients who were under antibio-
tic treatment at the time of PEG placement. Antibiotic
use was dependent on the patient’s known allergies.
Pull-type PEG was placed in 33 patients (58%) and
introducer PEG in 24 (42%). Table 1 shows that both
groups were comparable regarding patient characteris-
tics like age, sex and clinical status, expressed in serum
albumin levels and WHO performance status. All
patients underwent combined radiotherapy and che-
motherapy, starting at least 24 hours after PEG place-
ment. Retrospective analysis of the medical records
revealed several types of short-term complications: local
infection of the skin, prolonged bleeding of the gastro-
stomy, perforation of the GI tract, accidental removal of
the feeding tube, need for urgent surgery and death.
Overall, 4 (12%) complications were encountered in the
pull-type PEG group without mortality, whereas a total
of 11 (48%, P < 0.05) complications were seen in the
introducer PEG group (Table 2). In the remaining 242
patients, 24 (9.5%) complications were registered. Local
infection of the gastrostomy was encountered in both
Figure 2 Freka
® Pexact procedure showing introduction of the trocar with the peal-away sheet and final position of the temporary
PEG tube.
Table 1 Patients’ characteristics.
Pull-type PEG Introducer PEG
number patients (%) 33 (58) 24 (42)
male/female (%) 27/6 (82/18) 18/6 (75/25) P = 0.533
mean age ± SEM (years) 65 ± 2 64 ± 3 P = 0.774
mean serum albumin ± SEM (mg/dl) 3.2 ± 0.1 3.0 ± 0.1 P = 0.130
median WHO performance (25
th -7 5
th percentile) 1 (0-3) 2 (1-3) P = 0.212
SEM: standard error of the mean.
WHO: World Health Organization performance status.
P < 0.05: P value from statistical analysis (Unpaired Student’s t test for continuous variables and Mann-Whitney test for discontinuous variables, Chi square test
for contingency table statistics).
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fection and systemic antibiotic treatment. During the
study period, perforation of the GI tract was encoun-
tered in both groups. One pull-type PEG tube perfo-
rated the sigmoid colon needing surgical intervention.
This was an example of interposed colon due to inade-
quate location of the gastrostomy site by means of tran-
sillumination and finger indentation. In the introducer
PEG group, we observed 3 perforations and 2 of them
had severe clinical consequences leading to urgent sur-
gery in 2. One was only a shortlasting episode of pneu-
moperitoneum with mild abdominal discomfort without
further clinical significance. It is supposed to result from
inadequate insertion of the double needle with one
inside the stomach and the other one along the gastric
wall. Two patients needed surgical intervention due to
overt clinical signs of perforation. The first occurred
after accidental dislocation of the tube into the perito-
neal cavity shortly after the placement. During rescue
surgery, a laceration of the insertion site in the gastric
wall was seen. The second was noticed because of leak-
a g eo ft h et u b ef e e d i n gf r o mt h eg a s t r o s t o m ys i t ea n d
abdominal pain. Rescue surgery also showed a laceration
of the gastric wall but with the feeding tube still in
place. Unfortunately, both patients died at ICU shortly
after due to respiratory complications. Although statisti-
cal analysis revealed no significant difference in mortal-
ity rates (0% versus 8%, P = 0.091), the 2 deaths after
urgent rescue surgery are considered major drawbacks
of the introducer PEG procedure.
In the introducer PEG group, 1 prolonged bleeding
of the skin insertion site was observed. The bleeding
lasted for a couple of hours and was treated conserva-
tively by local pressure application. In addition, 1
patient from the introducer PEG group needed ICU
admission because of sepsis.D u r i n gc h e m o t h e r a p yh e
developed neutropenic fever and sepsis caused by a
local infection at the insertion site and the gastropexy
sutures. Culture showed Candida species both at the
gastrostomy site and in the blood. The PEG tube
needed to be removed.
Finally, accidental removal of the PEG tube within 8
weeks after placement was not seen in the pull-type
PEG group, whereas 4 patients (17%, P < 0.05) lost their
temporary feeding tube in the introducer PEG group. In
1 patient partial tube dislocation resulted in accidental
tube feeding into the peritoneal cavity with severe peri-
tonitis leading to urgent surgery, as described above.
Over the 3 years period complication rates of the
introducer PEG tube were randomly divided, without
correlation with time and endoscopist (data not shown).
Discussion
PEG tube feeding is the preferred method to provide
long-term tube feeding and its use is widespread nowa-
days [2]. However, PEG tube placement is an invasive
endoscopic procedure with an inherent risk of complica-
tions [13]. Major complications resulting from PEG tube
placement include peritonitis, hemorrhage, airway
aspiration, peristomal wound infection, buried bumper
symdrome, and gastrocolic fistula [3,14]. In the litera-
ture, complication rates of the conventional pull-type
PEG procedure vary from 1% to 30% [3,13-16]. Overall
complication rate of pull-type PEG tube placement was
9.5% in non-oncology patients in our retrospective ana-
lysis. In oncology patients with head and neck tumors,
the complication and mortality rates appear higher,
probably related to concomitant treatment with che-
motherapy and radiotherapy, reducing the patients’
immunity [17]. In this respect, it is noticed that in our
center oncologists start chemo- and radiotherapy 1 day
after the pull-type and introducer PEG procedures. For
safety reasons, one could argue that this immune sup-
pressive treatment should be postponed for 3 to 4 days
after PEG placement. However, the therapeutic strategy
was similar in both PEG procedure groups. Therefore,
the difference in complication rate between the two
methods cannot be accounted to the short interval
between PEG procedure and start of chemo- and
radiotherapy.
Patients with oesophageal or head and neck tumors
encompass a specific group of patients often requiring
PEG tube placement because of poor oral food intake
which may be related to the disease and/or its treat-
ment. Conventional pull-type PEG tube placement is
common in these patients. However, high-grade stenosis
may impede the introduction of a conventional upper
GI endoscope or the passage of the internal bumper of
the PEG tube. Moreover, there is a risk of entmetastases
at the gastrostomy when the feeding tube is pulled
across the malignant tumor through the stomach and
the abdominal wall [5]. Therefore, the introducer PEG
tube technique was developed and further adapted with
Table 2 Comparison of complications between Pull-type
and Introducer PEG.
Complications Pull-type PEG Introducer PEG
total (%) 4 (12) 11 (48) P = 0.004
local infection (%) 3 (9) 3 (12) P = 0.678
bleeding (%) 0 (0) 1 (4) P = 0.237
perforation (%) 1 (3) 3 (12) P = 0.167
tube removal (%) 0 (0) 4 (17) P = 0.015
surgery (%) 1(3) 3 (12) P = 0.167
mortality (%) 0 (0) 2 (8) P = 0.091
P < 0.05 unpaired Student’s t test.
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the commercially available Freka
® Pexact PEG from Fre-
senius Kabi AG. Initial data on its use and short-term
safety show low complications rates of less than 3% and
no mortality [6,9,18,19].
In contrast to the earlier reports, the present retro-
spective study reveals significant complication (48%) and
mortality (8%) rates within 8 weeks after introducer
PEG tube placement using the Freka
® Pexact in oncol-
ogy patients with oesophageal or head and neck malig-
nant tumors. After reviewing the patients’ medical files
and after discussion with the referring oncologists and
ear-nose-throat (ENT) specialists, both procedure-
related and patient-related complications were
encountered.
T h ed o u b l en e e d l ef r o mt h eF r e k a
® Pexact procedure
to perform the gastropexy, must be introduced simulta-
neously into the stomach. However, inadequate intro-
duction may lead to gastric perforation away from the
g a s t r o s t o m yw h e no n eo ft h en e e d l e sg l i d e sa l o n gt h e
outer gastric wall. Apparently, this complication does
not seem to be related to lack of experience since no
change in complication rate was observed over the 3
year period. The use of a single needle with T-bar
sutures to create the gastropexy may carry less risk of
inadequate introduction into the stomach. The use of
non-absorbable sutures may also represent an origin of
complication. If not removed appropriately, they may
increase the risk of local skin infection, especially in
immunocompromised patients under combined radio-
and chemotherapy. According to the manufacturer’s
guidelines, the sutures have to be removed 10 days after
gastropexy was performed. And although this was
always clearly marked in the follow-up section of the
endoscopy report, this was often forgotten by the refer-
ring oncologist. In combination with the patients’
reduced immunity due to chemotherapy, remaining
sutures may lead to local skin infections. Initial reports
show lower infections rates with the introducer PEG,
probabely because the tube does not pass the oral cavity
[19]. In non-immunocompromised patients, the use of
prophylactic antibiotics may even be not mandatory
[19]. Our results still advocate a stringent follow-up
together with the oncologist of the gastropexy and gas-
trostomy site and the use of antibiotics in immunocom-
promised patients. The use of absorbable sutures may
also limit local skin infections. Finally, according to the
manufacturer’s guidelines, the temporary PEG tube of
the Freka
® Pexact procedure needs to be replaced by a
definite PEG tube after 4 weeks, due to the weakness of
the internal balloon. Although this was also covered in
the follow-up section of the endoscopy report, in-time
replacement of the temporary PEG tube was also often
forgotten by the referring oncologist, leading to
accidental tube dislocation and even intraperitoneal tube
feeding. Immediate placement of a definite feeding tube
is advocated to decrease the risk of accidental tube
dislocation.
These results show that some of the complications
encountered were probably avoidable with a more strin-
gent follow-up of the gastropexy and gastrostomy in
these oncology patients. However, in these patients the
endoscopist is only involved in the actual placement of
the PEG tube, whereas general follow-up of the patient
is done by the oncologist who is focused on the medical
treatment of the underlying malignant disease. Appar-
ently, in this group of immunocompromised patients
this introducer PEG tube needs more attention as com-
pared to the classical pull-type PEG tube. Better instruc-
tions to the referring oncologist and better follow-up by
the endoscopist performing the PEG tube placement
seems mandatory.
Alternatives to endoscopy to perform gastrostomy
with tube feeding are radiological (fluoroscopy- or ultra-
sound-guided) placement or surgical placement with a
mini-laparotomy [20,21]. The method of choice to per-
form gastrostomy for tube feeding depends on the
patient’s clinical condition and comorbidities and the
physician’s experience and preference [22]. At the
Antwerp University Hospital endoscopic placement is
the preferred method, followed by surgical placement.
Radiological gastrostomy is not available.
Conclusion
The present retrospective study shows that severe
short-term complications may occur in patients with
oesophageal or head and neck tumors after placement
of the Freka
® Pexact introducer PEG tube, leading to
urgent surgical intervention and even death in a sub-
stantial amount of patients. Both procedure-related
and patient-related risk factors were identified. Better
follow-up of PEG tube daily care is mandatory. Also
improvements of the introducer PEG tube and alterna-
tives to PEG are suggested. Adaptations of this push-
type PEG procedure are under investigation [23]. Our
results suggest that for this specific group of patients
the conventional pull-type PEG is still the preferred
technique, if possible.
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